<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757168</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0513</org_study_id>
    <nct_id>NCT04757168</nct_id>
  </id_info>
  <brief_title>Changes in Regional and Global Cardiac Contractility After Stimulation in Scar Zone With the NOGA System</brief_title>
  <acronym>SCARPACE</acronym>
  <official_title>Changes in Regional and Global Cardiac Contractility After Stimulation in Scar Zone With the NOGA System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite a decrease in voltage amplitude in post-infarction scar areas, greater voltage&#xD;
      amplitudes are sometimes observed at the time of local extrasystoles mechanically induced by&#xD;
      catheters.&#xD;
&#xD;
      However, no study has investigated whether these electrical changes are associated with&#xD;
      mechanical changes in local contractility.&#xD;
&#xD;
      However, the voltage is closely correlated to the local contractile function as evidenced by&#xD;
      the use of the NOGA system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of LLS (linear local shortening) via the NOGATM system in percentage</measure>
    <time_frame>1month</time_frame>
    <description>Study the change in percentage of LLS during stimulation in a post-infarction scar zone identified by voltage mapping of the left ventricle with the NOGA system, compared to LLS in the same zone measured in atrial stimulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of global systolic function: left ventricular ejection fraction</measure>
    <time_frame>1month</time_frame>
    <description>Compare the left ventricular ejection fraction (in percentage) during stimulation in a scar area compared to a normal rhythm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the global systolic function: integral time velocity under aortic Translation results Evolution of the global systolic function: integral time velocity under aortic</measure>
    <time_frame>1month</time_frame>
    <description>Compare the integral time velocity under aortic (in centimeter) during stimulation in a scar area compared to a normal rhythm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the global systolic function: strain longitudinal global</measure>
    <time_frame>1month</time_frame>
    <description>Compare the strain longitudinal global(in percentage) during stimulation in a scar area compared to a normal rhythm</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>NOGA TM probe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NOGA TM probe</intervention_name>
    <description>Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient.&#xD;
Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure.</description>
    <arm_group_label>NOGA TM probe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients who should undergo ventricular tachycardia (VT) ablation after a myocardial&#xD;
        infarction according to current recommendations, namely: patients with ischemic heart&#xD;
        disease (ICD) and with episodes of sustained ventricular tachycardia responsible for&#xD;
        internal electric shocks by the implantable automatic defibrillator (ICD) (grade IB&#xD;
        recommendation)&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  patients with an MIC and an ICD, presenting a first episode of sustained ventricular&#xD;
             tachycardia (grade IIa, B recommendation)&#xD;
&#xD;
          -  Affiliated with a social protection scheme&#xD;
&#xD;
          -  Having signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication or non-indication for ventricular tachycardia ablation&#xD;
&#xD;
          -  Women who are pregnant or of childbearing age and without contraception, breastfeeding&#xD;
             women&#xD;
&#xD;
          -  Patients without ischemic heart disease&#xD;
&#xD;
          -  Patients under guardianship, curatorship or legal protection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne ROLLIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne ROLLIN, MD</last_name>
    <phone>5 61 32 24 29</phone>
    <phone_ext>+33</phone_ext>
    <email>rollin.a@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe MAURY, MD</last_name>
    <phone>5 61 34 10 18</phone>
    <phone_ext>+33</phone_ext>
    <email>maury.p@chu-toulouse.fr</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stimulation in cardiac scar area</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

